Denali Therapeutics Inc (NASDAQ: DNLI) open the trading on Wednesday, with great promise as it jumped 11.80% to $13.74, before settling in for the price of $12.29 at the close. Taking a more long-term approach, DNLI posted a 52-week range of $12.05-$33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 260.06%. Meanwhile, its Annual Earning per share during the time was -4.46%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -12.76%. This publicly-traded company’s shares outstanding now amounts to $142.63 million, simultaneously with a float of $125.71 million. The organization now has a market capitalization sitting at $2.00 billion. At the time of writing, stock’s 50-day Moving Average stood at $18.51, while the 200-day Moving Average is $23.10.
Denali Therapeutics Inc (DNLI) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Denali Therapeutics Inc’s current insider ownership accounts for 13.43%, in contrast to 88.02% institutional ownership. According to the most recent insider trade that took place on Jan 06 ’25, this organization’s Chief Medical Officer sold 12,255 shares at the rate of 20.22, making the entire transaction reach 247,796 in total value, affecting insider ownership by 178,580. Preceding that transaction, on Jan 07 ’25, Company’s Chief Medical Officer sold 2,907 for 20.81, making the whole transaction’s value amount to 60,495. This particular insider is now the holder of 175,673 in total.
Denali Therapeutics Inc (DNLI) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
Denali Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -12.76% and is forecasted to reach -2.58 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 7.03% through the next 5 years, which can be compared against the -4.46% growth it accomplished over the previous five years trading on the market.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Let’s observe the current performance indicators for Denali Therapeutics Inc (DNLI). It’s Quick Ratio in the last reported quarter now stands at 8.46. The Stock has managed to achieve an average true range (ATR) of 1.17.
In the same vein, DNLI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.58, a figure that is expected to reach -0.70 in the next quarter, and analysts are predicting that it will be -2.58 at the market close of one year from today.
Technical Analysis of Denali Therapeutics Inc (DNLI)
[Denali Therapeutics Inc, DNLI] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 28.18% While, its Average True Range was 1.20.
Raw Stochastic average of Denali Therapeutics Inc (DNLI) in the period of the previous 100 days is set at 7.94%, which indicates a major fall in contrast to 46.30% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 84.58% that was higher than 72.15% volatility it exhibited in the past 100-days period.
